Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Sanara MedTech (SMTI) Research & Development (2020 - 2025)

Historic Research & Development for Sanara MedTech (SMTI) over the last 6 years, with Q3 2025 value amounting to $1.0 million.

  • Sanara MedTech's Research & Development rose 3135.22% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year increase of 11261.21%. This contributed to the annual value of $5.7 million for FY2024, which is 3801.49% up from last year.
  • According to the latest figures from Q3 2025, Sanara MedTech's Research & Development is $1.0 million, which was up 3135.22% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, Sanara MedTech's Research & Development peaked at $3.8 million during Q4 2024, and registered a low of $35674.0 during Q3 2021.
  • For the 5-year period, Sanara MedTech's Research & Development averaged around $943855.4, with its median value being $986454.0 (2023).
  • Its Research & Development has fluctuated over the past 5 years, first soared by 287523.97% in 2022, then crashed by 3699.09% in 2023.
  • Over the past 5 years, Sanara MedTech's Research & Development (Quarter) stood at $300837.0 in 2021, then skyrocketed by 243.71% to $1.0 million in 2022, then tumbled by 36.99% to $651519.0 in 2023, then soared by 476.82% to $3.8 million in 2024, then plummeted by 72.6% to $1.0 million in 2025.
  • Its Research & Development stands at $1.0 million for Q3 2025, versus $1.3 million for Q2 2025 and $1.1 million for Q1 2025.